Navigation Links
Society of Gynecologic Oncologists 39th Annual Meeting on Women's Cancer to Include Sessions on HPV and Cervical Cancer
Date:3/10/2008

Eight Sessions to be Dedicated to the Prevention and Treatment of Cervical Cancer and HPV's Related Correlation to the Disease

CHICAGO, March 10 /PRNewswire-USNewswire/ -- It has been almost two years since the first vaccine to prevent cervical cancer was approved for regular clinical use, and the Society of Gynecologic Oncologists (SGO), the professional association for experts in women's cancer, will take a critical look at HPV and Cervical Cancer as well as the vaccine, its impact, and its future during the 2008 Annual Meeting on Women's Cancer, March 9 - 12, 2008, in Tampa, Florida.

Due to their background in obstetrics and gynecology - and specialized training in oncology, surgery, chemotherapy, radiation therapy and supportive care - gynecologic oncologists have the best understanding of cervical cancer, how it affects women, and how it can best be prevented. "At the Annual Meeting on Women's Cancer, no less than eight sessions have been built around varying aspects of this disease," explains SGO President, Andrew Berchuck, MD. "Of these, six specifically address the quadrivalent and bivalent vaccines that currently exist to prevent cervical cancer. We hope, by putting the spotlight on cervical cancer at this meeting, we can continue to extend and expand the knowledge about its prevention and treatability beyond the medical community to the general public in the hopes of reducing and even eliminating its existence."

The data presented during the meeting provides an array of new information on the vaccine and the human papillomavirus (HPV) - specifically HPV types 16 and 18, which cause 70 percent of all cervical cancers. For the gynecologic oncologists participating in SGO's Annual Meeting, these presentations and research will provide a first-look at some of the data emerging from preliminary studies on the long-term side effects of the vaccines, alternative benefits of vaccination, and genetic susceptibility to HPV. One such study, conducted by Warner K. Huh, MD, of the University of Alabama at Birmingham, found that participants who received the quadrivalent HPV vaccine had reduced incidence of abnormal Pap smears and a reduction in the need for cervical procedures like colposcopy and cervical biopsy.

Beyond the presentation of new research on the disease, a special symposium dedicated specifically to the issue of HPV vaccination is being held to provide a forum for discussion and debate on the "state" of vaccination against cervical cancer at the near two-year post-approval mark. "This is going to be a dynamic conversation," explains Mark Einstein, MD, the symposium's moderator. "Although the approval of the vaccine will likely be a huge benefit to women in their fight against cervical cancer, two years after the fact, there are still a lot of challenges being faced by both the medical community and the patient community. There are still questions about the groups of patients that would likely derive benefit from the vaccine. There is also some remaining and residual confusion about HPV and how it relates to cervical cancer among both physicians and patients, and in many cases women are unaware of their real risk of HPV infection."

Additional questions about vaccination for boys, "next generation" vaccines, and the pragmatic details of insurance coverage and physician reimbursement are also just beginning to surface, and will be addressed during the symposium as well. "The goal of this symposium and, really, the goal of this Annual Meeting is to educate... from physician to physician, physician to colleague, and, hopefully, ultimately, from physician to community," concludes Dr. Berchuck. "Cervical cancer is largely a preventable disease, and I can personally say that I would be very happy to never see a patient diagnosed with cervical cancer ever again. The first step toward achieving this end-result is arming the health care providers that see these women regularly - OB/GYNs, family practitioners, internists - with the 'best' information that currently exists on cervical cancer, HPV, and vaccination. A good deal of that information is borne from the conversations that will take place during our meeting."

The SGO is a national medical specialty organization of physicians who are trained in the comprehensive management of women with malignancies of the reproductive tract. Its purpose is to improve the care of women with gynecologic cancer by encouraging research, disseminating knowledge which will raise the standards of practice in the prevention and treatment of gynecologic malignancies, and cooperating with other organizations interested in women's health care, oncology and related fields. The Society's membership, totaling more than 1230, is primarily comprised of gynecologic oncologists, as well as other related medical specialists including medical oncologists, radiation oncologists and pathologists. SGO members provide multidisciplinary cancer treatment including chemotherapy, radiation therapy, surgery and supportive care. More information on the SGO can be found at http://www.sgo.org.


'/>"/>
SOURCE Society of Gynecologic Oncologists
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. American Chemical Societys Weekly PressPac -- March 5, 2008
2. MGT Comments on American Cancer Societys Decision to Endorse CT Colonography
3. MeadWestvaco and Autism Society of America Launch 2008 ASA Autism Awareness Cambridge Planner
4. MultiVu Video Feed: New National Colorectal Cancer Screening Guidelines Issued by the American Cancer Society
5. Milestone Scientific Announces Chicago Dental Societys 143rd Midwinter Meeting Proved Successful
6. Autism Society of America Hosts Day on the Hill
7. American Cancer Society to Open Doors to Its New Free Lodging and Support Center in NYC for Cancer Patients and Caregivers
8. Pump It Up and Autism Society of America Launch Bounce for Autism
9. American Chemical Societys weekly PressPac -- Feb. 27, 2008
10. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
11. Childrens Home Society & Family Services Achieves Full Hague Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology: